Navigation Links
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Date:12/4/2007

LEUVEN, Belgium, December 4 /PRNewswire/ --

- Microplasmin Shows Clear Promise in Back of the Eye Disease, With Treated Patients Achieving Macular Hole Closure and Traction Release Without Need for Vitrectomy

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular and eye diseases, will today present results from its Phase IIa MIVI IIT trial at the American Society of Retina Specialists (ASRS) 25th Annual Meeting in Indian Wells, California. The trial, which delivered positive clinical results in a number of the treated patients, was designed to evaluate both the safety and efficacy of microplasmin injection for the treatment of vitreomacular traction, an important cause of back of the eye disease. The results of the study will be presented by Professor Peter Stalmans, University Hospitals, Leuven, Belgium.

Vitreomacular traction is a condition where the vitreous (the central fluid part of the eye) has an abnormally strong adhesion to the surface of the macula (the part of the retina responsible for detailed vision). Due to this, the macula may become distorted creating poor or deficient vision. Vitreomacular traction can also lead to sight threatening conditions such as macular holes or macular edema.

In current practice, these conditions are treated by a highly skilled surgical procedure called vitrectomy. The procedure uses suction to remove the vitreous from the eye to induce posterior vitreous detachment or PVD, thereby alleviating the vitreomacular traction. The potential use of microplasmin to treat vitreomacular traction could therefore provide a more convenient, much less invasive approach, to both patients and physicians, for the treatment of important back of the eye diseases such as macular holes, diabetic macular edema, diabetic retinopathy in general, and even in age related macular degeneration (AMD), which are caused or exacerbated by the vitreous adhering to the retina abnormally. '/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
6. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
9. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Nueva Jersey , 22 de enero de ... Biomedical Research abre hoy su llamada a nominaciones para ... investigación científica ha hecho, o tiene el potencial para ... humana. Las nominaciones se aceptarán hasta el 15 de ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ...
(Date:12/24/2014)... Boston, MA (PRWEB) December 23, 2014 Earlier ... James L. Sherley, director of the Adult Stem Cell Technology ... overlooked and under appreciated unique property of adult tissue stem ... Misunderstood in the Past, Important for the Future,” embodied the ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... 15, 2011 BioNeutral Group, Inc. (OTC Bulletin ... science technology-based company, today announced that it has ... with Raymond Associates LLC, a Service Connected Certified ... Under the terms of the agreement, Raymond Associates ...
... DIEGO, March 14, 2011 OncoSec Medical, Inc. (OTC ... appointment of Mr. Punit Dhillon as president and chief ... (Logo:   http://photos.prnewswire.com/prnh/20110314/MM64943LOGO ) Mr. Dhillon ... the biotech industry. He was recently VP Finance & ...
... Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC ... announced today that Gary Rabin, the company,s interim chairman ... BIO-Europe Spring 2011 Conference, March 14-16, at the Milano ... scheduled for Wednesday, March 16, at 10:15 a.m. CET, ...
Cached Biology Technology:BioNeutral Enters into Global Sales and Distribution Agreement with Raymond Associates to Expand Market for Military-Grade Ygiene(TM) 2BioNeutral Enters into Global Sales and Distribution Agreement with Raymond Associates to Expand Market for Military-Grade Ygiene(TM) 3BioNeutral Enters into Global Sales and Distribution Agreement with Raymond Associates to Expand Market for Military-Grade Ygiene(TM) 4ACT Interim Chairman and CEO Gary Rabin to Present at BIO-Europe Spring 2011 Conference 2
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday Season may ... Acuity Market Intelligence reports that the long anticipated floodgates ... that intensifying demand for smart phones, tablets, and wearable ... market of 2.5 billion users with nearly 4.8 billion ...
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home Button ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first time ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming the ... at international borders. Over the past decade, ePassports, biometric ... to self process through border control via eGates and ... of airports, seaports, and land borders across the globe. ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... out to be just as important as what they eat, according ... The study, led by Dr. Nav Persaud, a family physician, found ... three to five and their levels of non-HDL or "bad" ... life. The paper appeared online in the Canadian Medical ...
... Vitamin D supplementation may help delay early onset of puberty ... presented Monday at The Endocrine Society,s 95th Annual Meeting in ... ages of 10 and 14. Boys undergo these changes later, ... is diagnosed in girls when sexual development begins before the ...
... declining worldwide and a major cause is a deadly fungus ... shows they can also die from this pathogen, contrary to ... spreads the disease. When researchers raised the frogs from ... strain of this pathogen, Batrachochytrium dendrobatidis , also called ...
Cached Biology News:Poor eating behaviors may put preschoolers at risk for later health problems 2Vitamin D supplementation may delay precocious puberty in girls 2Bullfrogs may help spread deadly amphibian fungus, but also die from it 2
... Art GLP facility with capabilities from ... fermentation. Coordinated process development from ... operation capable of simultaneous production runs ... Hosts include: Bacteria, Yeast, Fungi, ...
Request Info...
Immunogen: VDAC3 Protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
... 75 x 25 ... recommended for immunohistochemistry of paraffin-embedded sections, ... one end, markings will ... procedures, precleaned, ...
Biology Products: